- Conditions
- Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
- Interventions
- recombinant human CC10 (rhCC10), placebo
- Drug
- Lead sponsor
- Clarassance, Inc.
- Industry
- Eligibility
- 24 Weeks to 29 Weeks
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 4
- States / cities
- Wilmington, Delaware • Baltimore, Maryland • Mineola, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,080
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mesothelioma
- Interventions
- Magnesium sulfate, Normal Saline
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers, Bacterial Infections
- Interventions
- RPX2003 (Biapenem), Placebo
- Drug
- Lead sponsor
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Labor; Forced or Induced, Affecting Fetus or Newborn
- Interventions
- Intravenous normal saline administered at 250ml/hr, Intravenous normal saline administered at 125ml/hr
- Drug
- Lead sponsor
- MemorialCare Health System
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, mRNA-1283, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 64 Years
- Enrollment
- 30,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 150
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
- Conditions
- Atrial Fibrillation
- Interventions
- HBI-3000, Placebo
- Drug
- Lead sponsor
- HUYABIO International, LLC.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 4
- States / cities
- Naples, Florida • Springfield, Illinois • Tupelo, Mississippi + 1 more
- Conditions
- Covid19
- Interventions
- Remdesivir, Remdesivir Placebo, Corticosteroid
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
- Conditions
- Cardiac Catheterization, Blood Pressure, Heart Ventricles, Echocardiography, Heart Failure
- Interventions
- Sonazoid
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer
- Interventions
- Pembrolizumab, Placebo, Cisplatin, Capecitabine, 5-fluorouracil, Docetaxel, Oxaliplatin, Leucovorin
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,007 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 14
- States / cities
- Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 7 more
- Conditions
- Healthy Volunteers
- Interventions
- dapsone gel, dapsone gel vehicle, sodium lauryl sulfate, Normal saline
- Drug
- Lead sponsor
- Almirall, S.A.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 237 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Dexmedetomidine, Placebo
- Drug
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Zika Virus Infection
- Interventions
- IXIARO, Placebo, YF Vax 17D Strain, Zika Virus Purified Inactivated Vaccine (ZPIV)
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- Pain, Sickle Cell Disorder
- Interventions
- Normal saline, Ketamine
- Drug
- Lead sponsor
- Billy Sin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Pain, Postoperative, Pain, Chest
- Interventions
- Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally, Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Knee Osteoarthritis, Acute Pain, Anesthesia, Local, Regional Anesthesia
- Interventions
- ropivacaine 0.25% with epinephrine and 6mg dexamethasone, Saline
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Lumbar Spinal Stenosis, Thoracic Spinal Stenosis
- Interventions
- Tranexamic Acid, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis
- Interventions
- Aloe Vera Mouthwash, Standard of Care
- Dietary Supplement · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin
- Conditions
- Vomiting, Nausea, Children, Only
- Interventions
- Inhaled Isopropyl Alcohol, Oral Ondansetron, Inhaled Placebo
- Other · Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Meningitis, Meningococcal
- Interventions
- rLP2086 vaccine, control
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 5,715 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Tempe, Arizona + 28 more
- Conditions
- Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
- Interventions
- Arginine hydrochloride, Sodium Chloride 0.9%
- Drug
- Lead sponsor
- David K Carroll
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Bowel Obstruction
- Interventions
- IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension)
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Healthy, Latent Tuberculosis Infection (LTBI)
- Interventions
- Tuberculin Purified Protein Derivative
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Quality of Life, Pelvic Organ Prolapse, Prolapses, Vaginal Vault
- Interventions
- Dexamethasone, Normal saline
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Weston, Florida
- Conditions
- Obstetric Labour, Premature
- Interventions
- Retosiban IV infusion, Placebo IV infusion
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 45 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more